International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
Changes in symptoms and fibroid characteristics in women treated with ultrasound-guided high intensity focused ultrasound (USgHIFU) at Chris Hani Baragwanath Academic Hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Setzen Raphaela, Setzen Raymond, O'Donoghue Claire, Van Dyk Nico, Sengane Ayanda, Manyatsi Nomvuyo, Sarubdeo Shalya, Adam Yasmin
Аннотация
OBJECTIVE: The main objective was to describe women with fibroids who were treated with ultrasound-guided high intensity focused ultrasound (USgHIFU) at the Chris Hani Baragwanath Academic Hospital (CHBAH) and to evaluate the outcomes at least 6 months after treatment.
METHODS: This was a cross-sectional study using retrospectively collected data of women treated between November 2015 and December 2018 with USgHIFU at CHBAH. A clinical database that was used at the USgHIFU clinic and medical files were reviewed. The following data were retrieved; demographic information, characteristics of the fibroid (size, number, position, magnetic resonance imaging [MRI] intensity), symptoms before and after the procedure. Variables are described using descriptive statistics and were compared using a McNemar's chi2, t-test or Wilcoxon sign rank test.
RESULTS: The mean age, median body mass index (BMI) and median parity was 35 years (standard deviation [SD] ±5.43), BMI of 25.3 (interquartile range [IQR]: 22.31-29.05), parity 0 (IQR: 0-1; range: 0-6), respectively. The presenting symptoms were dysmenorrhea (85.41%), infertility (50.92%) and menorrhagia (67.69%). The proportion of dysmenorrhea decreased from 84.10% before treatment to 54.06% after treatment. Menorrhagia was reduced from 66.08% to 41.34%. The median size of fibroids changed from 38.00 to 26.88 cm3. These changes were statistically significant.
CONCLUSION: This is the first USgHIFU study that reports outcomes in a South African population. The treatment has resulted in a noticeable alleviation of symptoms and a measurable reduction in fibroid size and this was statistically significant and clinically relevant.
METHODS: This was a cross-sectional study using retrospectively collected data of women treated between November 2015 and December 2018 with USgHIFU at CHBAH. A clinical database that was used at the USgHIFU clinic and medical files were reviewed. The following data were retrieved; demographic information, characteristics of the fibroid (size, number, position, magnetic resonance imaging [MRI] intensity), symptoms before and after the procedure. Variables are described using descriptive statistics and were compared using a McNemar's chi2, t-test or Wilcoxon sign rank test.
RESULTS: The mean age, median body mass index (BMI) and median parity was 35 years (standard deviation [SD] ±5.43), BMI of 25.3 (interquartile range [IQR]: 22.31-29.05), parity 0 (IQR: 0-1; range: 0-6), respectively. The presenting symptoms were dysmenorrhea (85.41%), infertility (50.92%) and menorrhagia (67.69%). The proportion of dysmenorrhea decreased from 84.10% before treatment to 54.06% after treatment. Menorrhagia was reduced from 66.08% to 41.34%. The median size of fibroids changed from 38.00 to 26.88 cm3. These changes were statistically significant.
CONCLUSION: This is the first USgHIFU study that reports outcomes in a South African population. The treatment has resulted in a noticeable alleviation of symptoms and a measurable reduction in fibroid size and this was statistically significant and clinically relevant.